LifeNet Health's Dermacell AWM^®, the world's most-advanced acellular dermal matrix (ADM) for wound treatment, is the first human ADM available in India. This introduction provides access to proven therapy for millions of patients in India suffering from chronic wounds.

Each year, as many as 100,000 patients in India face amputation due to a chronic wound. With more than 65 million people with diabetes and 7.5 million new cases diagnosed each year, the incidence of severe wounds and amputation is steadily increasing in India. Dermacell AWM has been shown to effectively treat challenging wounds, thereby reducing the threat of amputation and its debilitating impacts such as decreased quality of life and increased mortality.

"We are proud to offer Dermacell AWM as the first therapy of its kind in India," said Rony Thomas, President and CEO of LifeNet Health, a global leader in regenerative medicine. "It's a truly unique clinical solution to help patients overcome severe wounds and avoid the devastating effects of amputation."

Dermacell AWM has been utilized as an effective treatment in the U.S., the European Union and Latin America prior to its availability in India. It is supported by multiple studies that show it can bring serious wounds to complete resolution with fewer applications than conventional care or other graft materials. 

Dermacell AWM is backed by the technologies and relentless commitment to quality that have made LifeNet Health a global leader in regenerative medicine. LifeNet Health's rigorous screening and production processes ensure the safety and effectiveness of each graft, and patented Matracell^® decellularization technology. The result is a wound-treatment solution that offers unsurpassed efficacy with unrivaled safety.

LifeNet Health will feature Dermacell AWM at the VSICON Annual Conference Oct. 17-20 in Hyderabad, India.